Kidney stone research is entering a new era, with scientists discovering that bacteria living inside stones may be the key to prevention, and novel treatments like microbial transplants and specialized binders are showing real promise in early trials. At the 2026 annual meeting of the ROCK Society (Research on Calculus Kinetics), the leading academic organization focused on kidney stone disease, researchers presented groundbreaking findings that could reshape how doctors approach stone prevention and treatment. What's Really Happening Inside Kidney Stones? For decades, doctors assumed kidney stones formed primarily from mineral buildup in urine. But new research reveals a more complex picture. Scientists recently discovered that bacteria living within kidney stones may actually trigger their formation and growth. In a study published in the Proceedings of the National Academy of Science, researchers examined kidney stones collected during lithotripsy procedures (a common surgical treatment) using four different imaging techniques, including electron microscopy and confocal microscopy. What they found was striking: bacterial biofilms, which are communities of bacteria surrounded by a protective layer, were embedded between the mineral layers of calcium-oxalate stones. Even more surprising, these bacteria were present in stones from patients who had no history of urinary tract infections and whose stone cultures came back negative. The bacteria appeared to serve as nucleation sites, essentially acting as seeds around which crystals grew. This discovery opens an entirely new avenue for stone prevention by targeting the bacterial component of stone formation. Can Changing Your Gut Bacteria Prevent Kidney Stones? One of the most novel approaches presented at the conference involves microbial transplant therapy (MTT), a treatment that modifies the gut microbiome to reduce stone-forming substances in urine. The FDA approved an investigational new drug application to test this therapy in patients with calcium-oxalate stones and high urinary calcium levels. In the first phase of the trial, six patients received the treatment after their gut bacteria were depleted with antibiotics. The results were encouraging. In five of the six patients, urinary oxalate (a key stone-forming compound) returned to nearly baseline levels after the microbial transplant. Two patients achieved normal calcium excretion despite high sodium intake and unchanged protein consumption. Three patients experienced clinically meaningful increases in citrate, a protective substance that inhibits stone formation. Additionally, four patients were able to stop taking preventive medications like potassium citrate or thiazide diuretics. The treatment was well-tolerated, with only minor gastrointestinal side effects. How to Reduce Kidney Stone Risk: New Prevention Strategies - Gut Oxalate Binding: A novel medication called ZO, a hydroxide-loaded anion exchanger, is being developed to bind oxalate in the digestive tract before it enters the bloodstream. In animal studies, ZO reduced urinary oxalate excretion by 40% after three weeks and lowered serum oxalate by 34% after one week, without causing metabolic side effects. - Empiric Preventive Therapy: The URINE trial compared two prevention approaches for recurrent kidney stones. Patients receiving standardized dietary counseling combined with two medications (indapamide and potassium citrate) showed improved urinary chemistry regardless of individual metabolic testing, making prevention more accessible to the majority of high-risk patients who never undergo 24-hour urine testing. - Bacterial Biofilm Targeting: Understanding that bacteria trigger stone formation opens the possibility of developing antibacterial or anti-biofilm therapies specifically designed to prevent calcium-oxalate stone genesis and growth. The URINE trial, conducted at Vanderbilt University Medical Center, highlights an important clinical challenge. Traditionally, doctors have recommended 24-hour urine testing to guide personalized stone prevention strategies. However, fewer than one in ten high-risk Americans actually undergo this testing, leaving the vast majority without any preventive intervention. The trial enrolled 56 adults with recurrent idiopathic calcium stone disease (average age 44.5 years, 54% women) and directly compared empiric therapy with selective therapy guided by urine testing. What New Tools Are Researchers Using to Study Kidney Stones? Beyond new treatments, researchers are building better infrastructure to study kidney stones at scale. The USDHub, a new publicly accessible database, now includes clinical characteristics and healthcare utilization data for more than 200,000 patients with urinary stone disease across nine pediatric and adult health systems. This database combines information from non-contrast CT scans, clinical notes, 24-hour urine chemistries, and stone analyses, using natural language processing and machine-learning algorithms to extract detailed information from imaging and medical records. This resource enables researchers to define and validate stone phenotypes at scale, evaluate variation in care pathways across different hospitals, conduct comparative effectiveness studies of prevention and procedural strategies, and develop risk prediction models for stone recurrence. The ability to study such a large, diverse population of stone formers will accelerate the discovery of new prevention and treatment approaches. The Kidney Stone Consortium, a newly formed patient advocacy and research organization, has also raised $100,000 to support research and is launching a "stone-to-stone" patient advocacy program, with a small grant expected to be announced this summer. These advances represent a fundamental shift in how researchers understand kidney stone disease. Rather than viewing stones as purely a mineral chemistry problem, scientists now recognize that bacteria, the gut microbiome, and individual metabolic factors all play interconnected roles. This more nuanced understanding is already translating into novel prevention strategies that could help the millions of Americans who experience recurrent kidney stones.
